I just checked out that company's stock and it doubled to .90 on that announcement! The specifity of the test, combined with a Pap smear was 95%, about the same as present cervical cancer tests (Pap/HPV); and about 65% sensitivity compared to the 27% from present tests. This is pretty good, but nothing like the numbers Biocurex puts up! And Recaf is not limited to any one kind of cancer. This demonstrates how undervalued this stock really is. I didn't check to see what the float is on SPRX, but I imagine it's not as low as BOCX. I'll check and post it! I think it is plainly obvious that we have discovered a once in a lifetime opportunity in Biocurex. Anyone on this board doubt it, I will purchase 10,000 of your shares @ .75 next week!!!
